Horses. Relief of pain in adult horses and yearlings. Clinical studies show that butorphanol tartrate alleviates abdominal pain associated with torsion, impaction, intussusceptions, spasmodic, tympanic and postpartum pain.
Dogs, cats. Relief of moderate to severe pain. Clinical studies have shown that butorphanol tartrate can provide suitable analgesia after a variety of surgical procedures, e.g. orthopaedic and soft tissue surgery. If administered pre-operatively, it will reduce the amount of analgesia required post-operatively.
When Butorgesic Injection is used alone as a sedative, sedation occurs in dogs but not in cats. In dogs and cats, profound sedation is achieved when Butorgesic Injection is used in conjunction with medetomidine hydrochloride, making it suitable for radiography, fracture exam or casting, coat de-matting, ear cleaning, wound management, anal gland flush and other minor procedures.
Use of butorphanol tartrate as a preanaesthetic in dogs has resulted in a dose related reduction in the dose of thiopentone sodium needed to induce anaesthesia, which may reduce the risk of anaesthetic respiratory depression. Preanaesthetic use in cats provides improved analgesia. Intravenous (IV) induction agents should be administered to effect.
Butorgesic Injection may be used as a triple anaesthetic in combination with medetomidine hydrochloride and ketamine hydrochloride.
Use the contents within 90 days of first broaching the vial. Discard the unused portion.
Horses. Analgesia. 0.1 mg/kg bodyweight by IV injection (1 mL/100 kg bodyweight). Analgesic effects will be evident within 15 minutes following injection and persist for about four hours. The dose may be repeated as required. Butorphanol use should not exceed 48 hours in any one treatment period.
Dogs. When administering by IV injection, inject slowly; do not inject as a bolus. For dogs weighing less than or equal to 10 kg, administration by insulin syringe is recommended to ensure accurate dosing. Due to the low volumes involved, great care should be taken when administering Butorgesic Injection to animals weighing under 5 kg. Analgesia. Administer by IV, IM or subcutaneous (SC) injection using aseptic technique. Give 0.2 to 0.3 mg/kg (0.2 to 0.3 mL/10 kg) bodyweight. Butorgesic Injection should be administered before terminating anaesthesia to provide analgesia in the recovery phase. Analgesic effects are seen within 15 minutes. For continuous analgesia, the dose may be repeated as required.
Sedation in combination with medetomidine hydrochloride. Give 0.1 mg/kg (0.1 mL/10 kg) together with 0.01 to 0.025 mg medetomidine hydrochloride/kg bodyweight, depending on the degree of sedation required, both to be administered by IM or IV injection. Allow 20 minutes for profound sedation to develop before commencing procedure. Reversal with atipamezole 0.05 to 0.1 mg/kg bodyweight results in sternal recumbency approximately five minutes later, and standing approximately a further two minutes later.
Preanaesthetic use. For use as a preanaesthetic, the Butorgesic Injection dose should be reduced to 0.1 to 0.2 mg/kg (0.1 to 0.2 mL/10 kg) administered 15 minutes prior to induction.
In combination with medetomidine and ketamine. Administer at 0.1 mg/kg (1 mL/10 kg) and 0.025 mg medetomidine/kg bodyweight by IM injection. Dogs become recumbent in approximately six minutes and lose their pedal reflex in approximately 14 minutes. Ketamine should be administered 15 minutes following the first injection at 5 mg/kg by IM injection. The pedal reflex returns approximately 53 minutes following the administration of the ketamine injection. Sternal recumbency is attained approximately 35 minutes later followed by standing a further 36 minutes later. Note. It is not advised to reverse this combination in dogs with atipamezole.
Cats. Cats should be weighed to ensure the correct dose is calculated. For cats weighing less than 10 kg, administration by insulin syringe is recommended for accuracy in dosing. Due to the low volumes involved, great care should be taken when administering Butorgesic Injection to animals weighing less than 5 kg. Use in cats weighing less than 5 kg bodyweight is not recommended.
Pre-operative analgesia. Give 0.4 mg/kg bodyweight (0.2 mL/5 kg) by SC or IM injection. It is reported in clinical studies that administering the dose five minutes prior to induction with either acepromazine and ketamine, or with xylazine and ketamine, given by IM injection, will provide analgesia when surgery commences. The arousal times will not be significantly altered. With IV induction agents, Butorgesic Injection should be administered 15 to 30 minutes prior to the administration of the anaesthetic.
Postoperative analgesia. Give 0.4 mg/kg bodyweight (0.2 mL/5 kg) administered by SC or IM injection 15 minutes prior to recovery.
Sedation in combination with medetomidine hydrochloride. Give 0.4 mg/kg bodyweight (0.2 mL/5 kg), with 0.05 mg medetomidine hydrochloride/kg bodyweight, both by either IM or SC injection. Local anaesthetic should be used for suturing. Reversal with atipamezole 0.125 mg/kg bodyweight results in sternal recumbency approximately four minutes later and standing one minute later.
Sedation in combination with medetomidine hydrochloride and ketamine. IM administration: give butorphanol 0.2 mL/5 kg (0.4 mg/kg) bodyweight, medetomidine hydrochloride 0.08 mg/kg bodyweight and ketamine 5 mg/kg by IM injection. Cats become recumbent in approximately two to three minutes and lose their pedal reflex in approximately three minutes following injection. Reversal with atipamezole 0.2 mg/kg bodyweight results in return of the pedal reflex two minutes later, sternal recumbency six minutes later and standing 31 minutes later. IV administration: give Butorgesic Injection 0.05 mL/5 kg (0.1 mg/kg), medetomidine hydrochloride 0.04 mg/kg bodyweight and ketamine 1.25 to 2.5 mg/kg by IV injection, depending on the depth of anaesthesia required.
Do not physically mix products in the same syringe.
Do not use in food producing species of animals. Do not use in horses that may be slaughtered for human consumption. Contraindicated for use in horses and dogs with a history of liver disease. Contraindicated for IV administration in cats under 5 kg bodyweight. The safe use of Butorgesic Injection in breeding horses, weanlings or foals has not been established and is therefore not recommended. Routine cardiac auscultation should be performed prior to use of this combination. Do not use this combination in horses with a pre-existing cardiac dysrhythmia or bradycardia. When used in conjunction with detomidine hydrochloride, this product is contraindicated for use in pregnant animals and animals suffering from colic.